DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for brachydactyly — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrachydactyly maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brachydactyly is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Indian hedgehog signaling molecule (IHH) — IHH is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet co3drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3K7J · 1.9 Å · ligand CARBONATE ION (CO3). Experimental structure, not a prediction.
What the evidence adds up to
Brachydactyly is a congenital shortening of the hands or feet caused by missing, deformed, or shortened bones, and can occur as an isolated trait or as part of a syndrome. The isolated forms are categorised into groups A through E, with considerable phenotypic overlap between groups. The majority of brachydactyly disease genes are directly or indirectly linked to the BMP pathway, which plays a pivotal role in digit and joint development; these genes function in a regulatory network that is deregulated in the disease state. Groups of diseases showing a common phenotypic pattern due to deregulation of a molecular network are suggested to be called molecular disease families.
A 2005 case report describes a male child with strikingly symmetrical brachydactyly and nail hypoplasia, extrahepatic biliary atresia, patent ductus arteriosus, seizures, developmental delay and cataracts. The authors state this combination of features has not previously been described and suggest it represents a new syndrome. A 2024 case report focuses on Brachydactyly type B, the rarest form, in an 8-month-old from the Philippines referred for a missing third toe; examination revealed a hypoplastic left third toe, confirmed by X-ray. The report notes that due to limited cases, type B is underreported.
A 2020 case report describes a rare case of Brachydactyly type A with variable presentation that caused difficulty in classifying the subtype. The condition is inherited as autosomal dominant, recessive, or sporadic varieties. Across all reports, there is no definitive treatment; management involves genetic counselling and therapy, and prognosis varies depending on severity and associated syndromes. Prenatal diagnosis is limited for isolated cases but useful for syndromic forms if a family mutation is known.
What is still missing is a definitive molecular classification that resolves the phenotypic overlap between brachydactyly subtypes, sufficient case collection to characterise the genetics of rare forms such as type B, and any clinical trial testing a pharmacological intervention. No drug is mentioned in any of these abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 2009 · 77 citations
The brachydactylies: a molecular disease family
AbstractBrachydactyly refers to shortening of the hands and/or feet due to missing, deformed, or shortened bones. It may occur as an isolated trait or as part of a syndrome. According to their pattern of skeletal involvement, the isolated brachydactyly forms have been categorized in the groups A-D including several subgroups. As in many other genetic conditions, there is considerable phenotypic overlap between the groups. The identification of the molecular causes of these conditions has offered insights into their pathogenesis. The generation of animal models has facilitated research on the pathogenic events during digit development that lead to the brachydactyly phenotype. These studies have shown that the BMP pathway plays a pivotal role in the normal development of digits and joints and that the majority of brachydactyly disease genes are directly or indirectly linked to this pathway. Together, these genes function in a regulatory network which is deregulated in the disease state. As a consequence of the close interactions within the network, overlapping phenotypes are generated that are, nevertheless, characterized by specific recognizable patterns. This principle does not only apply for the brachydactylies but is also valid for many other disease entities. Groups of diseases that show a common phenotypic pattern due to the deregulation of a molecular network are suggested to be called molecular disease families.
Brachydactyly with extrahepatic biliary atresia, patent ductus arteriosus and seizures ??? a new syndrome?
AbstractBrachydactyly is a relatively common congenital anomaly and can be associated with many other malformations. However, brachydactyly in association with biliary atresia is rare. We present a male child with strikingly symmetrical brachydactyly and nail hypoplasia, extrahepatic biliary atresia, patent ductus arteriosus, seizures, developmental delay and cataracts. This combination of features has not previously been described and we suggest that this case represents a new syndrome.
Journal of Surgical Case Reports · 2024 · 1 citations · open access
Brachydactyly type B: a rare case report and literature review
AbstractBrachydactyly is a genetic condition leading to shortened or absent digits in hands or feet. It can occur independently or as part of syndromes. This case focuses on Brachydactyly type B, the rarest form. An 8-month-old from the Philippines was referred due to a missing third toe. Examination revealed a hypoplastic left third toe. X-rays confirmed the finding. Treatment options were discussed, including conservative therapy and follow up. Diagnosis involved history, examination, and imaging. Prenatal diagnosis is limited for isolated cases but useful for syndromic forms if a family mutation is known. Prognosis varies depending on the severity and associated syndromes. Currently there is no definitive treatment; management involves genetic counseling and therapy. Due to limited cases, Type B is underreported, highlighting the need for more research into its genetics.
Indian Journal of Plastic Surgery · 2020 · 1 citations · open access
A Rare Case of Brachydactyly Type A Presenting a Dilemma in Clinical Classification of the Subtype
AbstractBrachydactyly is a condition characterized by congenital shortening of digits or toes, which occurs due to short phalanges, metacarpal or metatarsal bones.[1] This condition may involve more than one digit or toe and depending on the involvement of the underlying bones and number of digits this condition, it is classified into five types (type A-type E).[2] They are inherited as autosomal dominant, recessive, or sporadic varieties. In this report, a rare case of Brachydactyly type A is presented, which had a variable presentation, causing difficulty in classifying the subtype.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
